about
Docetaxel does not impair skeletal muscle force production in a murine model of cancer chemotherapyThe FOXM1-ABCC5 axis contributes to paclitaxel resistance in nasopharyngeal carcinoma cells.Medication-associated gastrointestinal tract injury.Cholic acid-based novel micellar nanoplatform for delivering FDA-approved taxanes.
P2860
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Treatment regimens of classical and newer taxanes.
@en
type
label
Treatment regimens of classical and newer taxanes.
@en
prefLabel
Treatment regimens of classical and newer taxanes.
@en
P2860
P1476
Treatment regimens of classical and newer taxanes.
@en
P2093
Markus Joerger
P2860
P2888
P304
P356
10.1007/S00280-015-2893-6
P577
2015-11-20T00:00:00Z
P6179
1033047131